Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Imatinib Mesylate

Monica P. Davey
Kathy Wilkinson
CJON 2002, 6(2), 118-120 DOI: 10.1188/02.CJON.118-120

Imatinib mesylate is indicated in the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, the accelerated phase of disease, or in the chronic phase of disease after not responding to interferon-alpha therapy. Studies are being conducted to evaluate the drug in treating gastrointestinal (GI) stromal tumors (GIST, a form of sarcoma), small-cell lung cancer, prostate cancer, and glioblastoma.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or